A research group led by Prof. Dennis Kyle at the University of Georgia, USA, has developed a high-throughput P. vivax liver-stage assay that uses human primary liver cells. Using sporozoites supplied by partners in Thailand and Cambodia, the team has now, for the first time in the history of P. vivax research, been able to screen two small-scale libraries of chemical entities, representing around 30,000 data points. Several potential radical cure molecules have been identified and chemical optimization is underway with a view to launching a full drug discovery programme. If all progresses as expected, this could potentially lead to a new clinical candidate for relapsing P. vivax malaria within the next 4 years.
Read more in Chapter 5 of our Annual Report: Next generation tools to tackle relapses.
Updated August 2019